Analyst warns Inspire Medical faces growth hurdles through 2028

A Bank of America analyst warned that Inspire Medical faces coding and competition challenges that could persist through 2028 ^[1].

These obstacles are significant because they threaten the revenue growth and market adoption of the company's sleep-apnea devices. If reimbursement hurdles and drug competition limit the patient pool, the company may struggle to meet long-term financial projections.

The analyst identified two primary drivers for these headwinds. First, the company is dealing with coding reimbursement issues that affect how the device is paid for by insurers. "We see a coding challenge that could impact revenue through 2028," the analyst said ^[1].

Second, the rise of GLP-1 weight-loss drugs is creating a new competitive landscape. Because weight loss can reduce the severity of obstructive sleep apnea, these drugs may decrease the number of patients seeking surgical implants. "The GLP-1 market is creating headwinds for Inspire’s growth trajectory," the analyst said ^[2].

Inspire Medical specializes in implantable pulse generators that stimulate the hypoglossal nerve to keep the airway open during sleep. While the technology offers an alternative to continuous positive airway pressure (CPAP) machines, the analyst suggests the intersection of insurance coding and pharmaceutical advancements creates a precarious environment for the firm's expansion.

Analysts continue to monitor how the medical device sector adapts to the rapid adoption of weight-loss medications. The potential for GLP-1 drugs to treat the root cause of sleep apnea, excess weight, poses a structural risk to the demand for permanent surgical interventions ^[2].